arrow_back Back to App

Home IVIG Access for Medicare Patients

This bill aims to improve access to intravenous immune globulin (IVIG) treatment at home for individuals with chronic neurological conditions like chronic inflammatory demyelinating polyneuropathy (CIDP) or multifocal motor neuropathy (MMN). Through this demonstration project, eligible Medicare beneficiaries will be able to receive necessary treatment in the comfort of their own homes, potentially enhancing their quality of life and reducing the burden of medical facility visits.
Key points
A 5-year demonstration project will allow Medicare patients with CIDP or MMN to receive IVIG treatment at home.
The project will evaluate the benefits of in-home administration, including costs and impact on care access.
Participation is voluntary and limited to up to 3,000 Medicare beneficiaries not enrolled in Medicare Advantage plans.
The bill establishes specific payment rules for the drug and in-home nursing services, considering longer infusion times for these conditions.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_3808
Sponsor: Rep. Blumenauer, Earl [D-OR-3]
Process start date: 2021-06-11
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Medicare IVIG Access Enhancement Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_3808.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-06-11.

What are the main provisions?

Key points include:

  • A 5-year demonstration project will allow Medicare patients with CIDP or MMN to receive IVIG treatment at home.
  • The project will evaluate the benefits of in-home administration, including costs and impact on care access.
  • Participation is voluntary and limited to up to 3,000 Medicare beneficiaries not enrolled in Medicare Advantage plans.
  • The bill establishes specific payment rules for the drug and in-home nursing services, considering longer infusion times for these conditions.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Blumenauer, Earl [D-OR-3].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health Benefits